Dr. Jeremy Schmit
Antibodies are a rapidly growing segment of the drug discovery industry and are particularly promising as anticancer agents due to their high specificity. These molecules can target tumor cells either by invoking an immune response or as carriers to bring traditional chemotherapy agents directly to the tumor. However, antibodies are large, complicated molecules, posing many practical challenges for manufacturing, storage, and delivery. We are studying how antibodies interact in concentrated solutions to develop strategies to mitigate problems like aggregation and high viscosities in formulations of therapeutic antibodies. Our goal is to develop tools that can identify problematic molecules early in the development pipeline where small modifications may be easily (and cheaply) implemented.